Biocatalytic approaches applied to the synthesis of nucleoside prodrugs

Biotechnology Advances

Volumn 33, Issue 5, 2015, Pages 412-434

  Iglesias, Luis E ^a   Lewkowicz, Elizabeth S ^a   Medici, Rosario ^b   Bianchi, Paola ^a   Iribarren, Adolfo M ^a,c  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

Author keywords

Biocatalysis; Chemoenzymatic synthesis; Nucleosides; Nucleotides; Prodrugs

Indexed keywords

BIOCATALYSTS; BIOTECHNOLOGY; CATALYSIS; NUCLEOTIDES;

ANTITUMOUR ACTIVITY; BIOACTIVE MOLECULES; BIOCATALYSIS; CHEMO-ENZYMATIC SYNTHESIS; NUCLEOSIDE ANALOGUES; NUCLEOSIDES; PRODRUGS; THERAPEUTIC EFFICACY;

BIOMOLECULES;

BIOACTIVITY; CATALYSIS; DRUG; ENZYME ACTIVITY;

NUCLEOSIDE; NUCLEOTIDE; PRODRUG;

BIOCATALYSIS; BIOTECHNOLOGY;

BIOCATALYSIS; BIOTECHNOLOGY; NUCLEOSIDES; NUCLEOTIDES; PRODRUGS;

EID: 84931004925     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.03.009     Document Type: Review

References (184)

1. Afshar S., Sawaya M.R., Morrison S.L. Structure of a mutant human purinenucleoside phosphorylase with the prodrug, 2-fluoro-2-deoxyadenosine and the cytotoxic drug, 2-fluoroadenine. Protein Sci 2009, 18:1107-1114.
2. Albert A. Chemical aspects of selective toxicity. Nature 1958, 182:421-422.
3. Allen M., Qin W., Moreau F., Moffatt B. Adenine phosphoribosyltransferase isoforms of Arabidopsis and their potential contributions to adenine and cytokinin metabolism. Physiol Plant 2002, 115:56-68.
4. Alvarado L.J., Le Blanc R.M., Longhini A.P., Keane S.C., Jain N., Yildiz Z.F., et al. Regioselective chemical-enzymatic synthesis of pyrimidine nucleotides facilitates RNA structure and dynamics studies. Chembiochem 2014, 15:1573-1577.
5. Anand R., Kaminski P.A., Ealick S.E. Structures of purine 2'-deoxyribosyltransferase, substrate complexes, and the ribosylated enzyme intermediate at 2.0Å resolution. Biochemistry 2004, 43:2384-2393.
6. Anderson V.R., Perry C.M. Fludarabine: a review of its use in non-Hodgkin's lymphoma. Drugs 2007, 67:1633-1655.
7. Anderson R.D., Griffy K.G., Jung D., Dorr A., Hulse J.D., Smith R.B. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995, 17:425-432.
8. Arent S., Kadziola A., Larsen A., Neuhard J., Jensen K.F. The extraordinary specificity of xanthine phosphoribosyltransferase from Bacillus subtilis. Elucidated by reaction kinetics, ligand binding, and crystallography. Biochemistry 2006, 45:6615-6627.
9. Asano Y., Mihara Y., Yamada H. A new enzymatic method of selective phosphorylation of nucleosides. J Mol Catal B: Enzym 1999, 6:271-277.
10. Babich L., Hartog A.F., van der Horst M.A., Wever R. Continuous-flow reactor-based enzymatic synthesis of phosphorylated compounds on a large scale. Chem Eur J 2012, 18:6604-6609.
11. Baldessari A., Iglesias L.E. Lipases in green chemistry: acylation and alcoholysis on steroids and nucleosides. Lipases and phospholipases - methods and protocols 2012, Springer, New York, [Chapter 26]. G. Sandoval (Ed.).
12. Balzarini J., De Clercq E. The antiviral activity of 9-β-d-arabinofuranosyladenine is enhanced by the 2',3'-dideoxyriboside, the 2',3'-didehydro-2',3'-dideoxyriboside and the 3'-azido-2',3'-dideoxyriboside of 2,6-diaminopurine. Biochem Biophys Res Commun 1989, 159:61-67.
13. Barai V.N., Kvach S.V., Zinchenko A.I., Mikhailopulo I.A. An improved method for the enzymatic transformation of nucleosides into 5'-monophosphates. Biotechnol Lett 2004, 26:1847-1850.
14. Bavaro T., Rocchietti S., Ubiali D., Filice M., Terreni M., Pregnolato M. A versatile synthesis of 5-functionalized nucleosides through regioselective enzymatic hydrolysis of their peracetylated precursors. Eur J Org Chem 2009, 2009:1967-1975.
15. Bergman A.M., Kuiper C.M., Voorn D.A., Comijn E.M., Myhren F., Sandvold M.L., et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004, 67:503-511.
16. Bertolini A., Ferreri A., Guerzoni S., Tacchi R., Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev 2006, 12:250-275.
17. Bi Y.H., Du W.Y., Wang Z.Y., Chen X.M., Nie L.H., Zong M.H. Understanding the behaviour of Thermomyces lanoginosus lipase in acylation of pyrimidine nucleosides possessing 2'-substituents. Appl Biochem Biotechnol 2014, 174:556-563.
18. Birischevskaya L.L., Kvach S.V., Sivets G.G., Kalinichenko E.N., Zinchenko A.I., Mikhailopulo A.I. A comparison of enzymatic phosphorylation and phosphatidylation of β-l and β-d-nucleosides. Biotechnol Lett 2007, 29:585-591.
19. Blazek J., Jansa P., Baszczynski O., Kaiser M.M., Otmar M., Krecmerova M., et al. An enzymatic glycosylation of nucleoside analogues using β-galactosidase from Escherichia coli. Bioorg Med Chem Lett 2012, 20:3111-3118.
20. Bobeck D.R., Schinazi R.F., Coats S.J. Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir Ther 2010, 15:935-950.
21. Boutureira O., Matheu M.I., Díaz Y., Castillón S. Advances in the enantioselective synthesis of carbocyclic nucleosides. Chem Soc Rev 2013, 42:5056-5072.
22. Boyle G.A., Edlin C.D., Li Y., Liotta D.C., Morgans G.L., Musonda C.C. Enantioselective synthesis of the carbocyclic nucleoside (-)-abacavir. Org Biomol Chem 2012, 10:1870-1876.
23. Brandl M., Wu X., Holper M., Hong L., Jia Z., Birudaraj R., et al. Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. Drug Dev Ind Pharm 2008, 34:683-691.
24. Breistol K., Balzarini J., Sandvold M.L., Myhren F., Martinsen M., De Clercq E., et al. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res 1999, 59:2944-2949.
25. Brown N.A. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin Investig Drugs 2009, 18:709-725.
26. Caron J., Reddy L.H., Lepêtre-Mouelhi S., Wack S., Clayette P., Rogez-Kreuz C., et al. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. Bioorg Med Chem Lett 2010, 20:2761-2764.
27. Chen H., Boudinot F.D., Chu C.K., McClure H.M., Schinazi R.F. Pharmacokinetics of (-)-β-d-2-aminopurine dioxolane and (-)-β-d-2-amino-6-chloropurinedioxolane and their antiviral metabolite (-)-β-d-dioxolane guanine in rhesus monkeys. Antimicrob Agents Chemother 1996, 40:2332-2336.
28. Chen G., Tang B., Yang B.Y., Chen J.X., Zhou J.H., Li J.H., et al. Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model. Appl Microbiol Biotechnol 2013, 97:4393-4401.
29. Chhikara B.S., Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin Drug Deliv 2010, 7:1399-1414.
30. Crance J.M., Scaramozzino N., Jouan A., Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003, 58:73-79.
31. Dahan A., Zimmermann E.M., Ben-Shabat S. Modern prodrug design for targeted oral drug delivery. Molecules 2014, 19:16489-16505.
32. De Benedetti E., Rivero C.W., Britos C.N., Lozano M.E., Trelles J.A. Biotransformation of 2,6-diaminopurine nucleosides by immobilized Geobacillus stearothermophilus. Biotechnol Prog 2012, 28:1251-1255.
33. De Clercq E. A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 2011, 51:1-24.
34. Deville-Bonne D., El Amri C., Meyer P., Chen Y., Agrofoglio L.A., Janin J. Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties. Antiviral Res 2010, 86:101-120.
35. Ding Q., Ou L., Wei D., Wei X., Xu Y., Zhang C. Enzymatic synthesis of nucleosides by nucleoside phosphorylase co-expressed in Escherichia coli. J Zhejiang Univ Sci 2010, 11:880-888.
36. Faletto M.B., Miller W.H., Garvey E.P., St.Clair M.H., Daluge S.M., Good S.S. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997, 41:1099-1107.
37. Fernández-Lucas J., Acebal C., Sinisterra J.V., Arroyo M., de la Mata I. Lactobacillus reuteri 2'-deoxyribosyltransferase, a novel biocatalyst for tailoring of nucleosides. Appl Environ Microbiol 2010, l76:1462-1470.
38. Fernández-Lucas J., Harris R., Mata-Casar I., Heras A., de la Mata I., Arroyo M. Magnetic chitosan beads for covalent immobilization of nucleoside 2'-deoxyribosyltransferase: application in nucleoside analogues synthesis. J Ind Microbiol Biotechnol 2013, 40:955-966.
39. Ferrero M., Gotor V. Biocatalytic selective modifications of conventional nucleosides, carbocyclic nucleosides and C-nucleosides. Chem Rev 2000, 100:4319-4347.
40. Ferrero M., Gotor V. Chemoenzymatic transformations in nucleoside chemistry. Monatsh Chem 2000, 131:585-616.
41. Fresco-Taboada F., de la Mata I., Arroyo M., Fernández-Lucas J. New insights on nucleoside 2'-deoxyribosyltransferases: a versatile biocatalyst for one-pot one-step synthesis of nucleoside analogs. Appl Microbiol Biotechnol 2013, 97:3773-3785.
42. Fridland A., Connelly M.C., Robbins T.J. Tiazofurin metabolism in human limphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidase. Cancer Res 1986, 46:532-537.
43. Gao W.L., Li N., Zong M.H. Highly regioselective synthesis of undecylenic acid esters of purine nucleosides catalyzed by Candida antarctica lipase B. Biotechnol Lett 2011, 33:2233-2240.
44. Gao W.L., Liu H., Li N., Zong M.H. Regioselective enzymatic undecylenoylation of 8-chloroadenosine and its analogs with biomass-based 2-methyltetrahydrofuran as solvent. Bioresour Technol 2012, 118:82-88.
45. Gao W.L., Li N., Zong M.H. Enzymatic acylation of nucleosides in biomass-derived 2-methyltetrahydrofuran: kinetic study and enzyme substrate recognition. J Biotechnol 2013, 164:91-96.
46. Gaubert G., Gosselin G., Boudou V., Imbach J.-L., Eriksson S., Maury G. Low enantioselectivities of human deoxycytidine kinase and human deoxyguanosine kinase with respect to 2'-deoxyadenosine and 2'-deoxyguanosine and their analogs. Biochimie 1999, 81:1041-1047.
47. Golitsina N.L., Danehy F.T., Fellows R., Cretton-Scott E., Standring D.N. Evaluation of the role of three candidate human kinases in the conversion of the hepatitis C virus inhibitor 2_-C-methyl-cytidine to its 5'-monophosphate metabolite. Antiviral Res 2010, 85:470-481.
48. Gudiño E.D., Iglesias L.E., Ferreira M.L. A rational approach to the regioselective deacetylation of 2',3',5'-tri-O-acetyluridine by Novozym 435 catalysed alcoholysis. Biochim Biophys Acta 2012, 1824:627-636.
49. Heimbach T., Fleischer D., Kaddoumi A. Overcoming poor aqueous solubility of drugs for oral delivery. Prodrugs: challenges and rewards 2007, 160-199. Springer, New York. S.V. Borchart, M. Hageman, R. Oliya, H. Maag, J.W. Tilley (Eds.).
50. Herbal K., Kitteringham J., Voyle M., Whitehead A.J. Synthesis of the enantiomer of nelarabine. Tetrahedron Lett 2005, 46:2961-2964.
51. Holguin J., Cardinaud R., Salemink C.A. Trans-N-deoxyribosylase: substrate specificity studies. Eur J Biochem 1975, 54:515-520.
52. Huttunen K.M., Raunio H., Rautio J. Prodrugs - from serendipity to rational design. Pharmacol Rev 2011, 63:750-771.
53. Ireland C., Leeson P.A., Castaner J. Lobucavir antiviral. Drugs Future 1997, 22:359-370.
54. Jhansi Rani V., Raghavendra A., Kishore P., Nanda Kumar Y., Hema Kumar K., Jagadeeswarareddy K. Synthesis and biological activity evaluation of cytidine-5'-deoxy-5-fluoro-N-[(alkoxy/aryloxy)] carbonyl-cyclic 2',3'-carbonates. Eur J Med Chem 2012, 54:690-696.
55. Johnson M.A., Fridland A. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol Pharmacol 1989, 36:291-295.
56. Johnston P.G., Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 2001, 12:639-646.
57. Jordheim L.P., Durantel D., Zoulim F., Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature 2013, 12:447-464.
58. Jung D., Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999, 39:800-804.
59. Kaminski P.A., Labesse G. Phosphodeoxyribosyltransferases, designed enzymes for deoxyribonucleotides synthesis. J Biol Chem 2013, 288:6534-6541.
60. Keller P.M., McKee S.A., Fyfe J.A. Cytoplasmic 5'-nucleotidase catalyzes acyclovir phosphorylation. J Biol Chem 1985, 260:8664-8667.
61. Keough D.T., Ng A.-L., Winzor D.J., Emmerson B.T., de Jersey J. Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme. Mol Biochem Parasitol 1999, 98:29-41.
62. Kisor D.F. Nelarabine use in leukemias. Drugs Today 2006, 42:455-465.
63. Kitos T.E., Tyrrell D.L.J. Intracellular metabolism of 2',3'-dideoxynucleosides in duck hepatocyte primary cultures. Biochem Pharmacol 1995, 49:1291-1302.
64. Knecht W., Mikkelsen N.E., Clausen A.R., Willer M., Eklund H., Gojkovic Z., et al. Drosophila melanogaster deoxyribonucleoside kinase activates gemcitabine. Biochem Biophys Res Commun 2009, 382:430-433.
65. Kokil G.R., Rewatkar P.V. Bioprecursor prodrugs: molecular modification of the active principle. Mini Rev Med Chem 2010, 10:1316-1330.
66. Koukourakis G.V., Kouloulias V., Koukourakis M.J., Zacharias G.A., Zabatis H., Kouvaris J. Efficacy of the oral fluorouracil prodrug capecitabine in cancer treatment: a review. Molecules 2008, 13:1897-1922.
67. Krenitsky T.A., Papaioannou R., Elion G.B. Human hypoxanthine phosphoribosyltransferase: purification, properties, and specificity. J Biol Chem 1969, 244:1263-1270.
68. Krenitsky T.A., Averett D.R., Wilson J.D., Moorman A.R., Koszalka G.W., Chamberlain S.D., et al. PCT Int Appl 1992, 54. [WO 9201456 A1 19920206 CAN 116:236100 AN 1992:236100].
69. Krungkrai S.R., Aoki S., Palacpac N.M.Q., Sato D., Mitamura T., Krungkrai J., et al. Human malaria parasite orotate phosphoribosyltransferase: functional expression, characterization of kinetic reaction mechanism and inhibition profile. Mol Biochem Parasitol 2004, 134:245-255.
70. Lavandera I., Fernández S., Magdalena J., Ferrero M., Kazlauskas R.J., Gotor V. An inverse substrate orientation for the regioselective acylation of 3',5'-diaminonucleosides catalyzed by Candida antarctica lipase B?. Chembiochem 2005, 6:1381-1390.
71. Lefebvre I., Brigaud C.P., Pompon A., Aubertin A.-M., Girardet J.-L., Kim A., et al. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidin-5'-monophosphate. J Med Chem 1995, 38:3941-3950.
72. Lehouritis P., Springer C., Tangney M. Bacterial-directed enzyme prodrug therapy. J Control Release 2013, 170:120-131.
73. Lewkowicz E.S., Iribarren A.M. Nucleoside phosphorylases. Curr Org Chem 2006, 10:1197-1215.
74. Li X.F., Zong M.H., Yang R.D. Novozym 435-catalysed regioselective acylation of 1-β-d-arabinofuranosylcytosine in a cosolvent mixture of pyridine and isopropyl ether. J Mol Catal B: Enzym 2006, 38:48-53.
75. Li X.F., Zong M.H., Wu H., Lou W.Y. Markedly improving Novozym 435-mediated regioselective acylation of 1-β-d-arabinofuranosylcytosine by using cosolvent mixtures as the reaction media. J Biotechnol 2006, 124:552-560.
76. Li F., Maag H., Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 2008, 97:1109-1134.
77. Li N., Smith T.J., Zong M.H. Biocatalytic transformations of nucleoside derivatives. Biotechnol Adv 2010, 28:348-366.
78. Li X.F., Zong M.H., Zhao G.L. Efficient synthesis of 5'-O-laurate of 1-β-d-arabinofuranosylcytosine via highly regioselective enzymatic acylation in binary solvent mixtures. Bioorg Med Chem Lett 2010, 20:4125-4127.
79. Li X.F., Zong M.H., Zhao G.L. Highly regioselective enzymatic synthesis of 5'-O-stearate of 1-β-d-arabinofuranosylcytosine in binary organic solvent mixtures. Appl Microbiol Biotechnol 2010, 88:57-63.
80. Li X.F., Zong M.H., Zhao G.L., Yu Y.G., Wu H. Application of organic solvent system for lipase-catalyzed regioselective benzoylation of 1-β-d-arabinofuranosylcytosine. Biotechnol Bioprocess Eng 2010, 15:608-613.
81. Li X.F., Lu Z.H., Liu H.W., Zhao G.L., Wu H., Yuan K., et al. Dependence of catalytic performance of a freeze-dried whole-cell biocatalyst of Pseudomonas fluorescens in regioselective acetylation of 1-β-d-arabinofuranosylcytosine on growth conditions. Process Biochem 2012, 47:1826-1831.
82. Li X.F., Lu Z.H., Zhao G.L., Wu H., Yu Y.G. A facile whole-cell biocatalytic approach to regioselective synthesis of monoacylated 1-β-d-arabinofuranosylcytosine: influence of organic solvents. Bioresour Technol 2012, 114:6-11.
83. Li X.F., Zhu Z., Zhao G.L., Yu Y.G., Lai F.R., Wu H. A novel biocatalytic approach to acetylation of 1-β-d-arabinofuranosylcytosine by Aspergillus oryzae whole cells in organic solvents. Appl Microbiol Biotechnol 2012, 93:143-150.
84. Liang S., Li W., Gao T., Zhu X., Yang G., Ren D. Enzymatic synthesis of 2'-deoxyadenosine and 6-methylpurine-2'-deoxyriboside by Escherichia coli DH5α overexpressing nucleoside phosphorylases from Escherichia coli BL21. J Biosci Bioeng 2010, 110:165-168.
85. Lichtenstein J., Barner H.D., Cohen S.S. The metabolism of exogenously supplied nucleotides by Escherichia coli. J Biol Chem 1960, 235:457-465.
86. Liu Z.-Q., Zhang L., Sun L.-H., Li X.-J., Wan N.-W., Zheng Y.-G. Enzymatic production of 5'-inosinic acid by a newly synthetized acid phosphatase/phosphotransferase. Food Chem 2012, 134:948-956.
87. Long M.C., Shaddix S.C., Moukha-chafiq Q., Maddry J.A., Nagy L., Parker W.B. Structure-activity relationship for adenosine kinase from Mycobacterium tuberculosis II. Modifications to the ribofuranosyl moiety. Biochem Pharmacol 2008, 75:1588-1600.
88. Ma S., Zhao L., Zhu Z., Liu Q., Xu H., Johansson M., et al. The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster as a therapeutic suicide gene of breast cancer cells. J Gene Med 2011, 13:305-311.
89. Maag H. Overcoming poor permeability - the role of prodrugs for oral drug delivery. Drug Discov Today Technol 2012, 9:121-130.
90. Mackman R.L., Cihlar T. Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics. Annu Rep Med Chem 2004, 39:305-321.
91. Manouilov K.K., Manouilova L.S., Boudinot F.D., Schinazic R.F., Chu C.K. Biotransformation and pharmacokinetics of prodrug 9-(β-d-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(β-d-1,3-dioxolan-4-yl)guanine in mice. Antiviral Res 1997, 35:187-193.
92. Martínez Montero S., Fernández S., Sanghvi Y.S., Gotor V., Ferrero M. Enzymatic parallel kinetic resolution of mixtures of d/l 2'-deoxy and ribonucleosides: an approach for the isolation of β-l-nucleosides. J Org Chem 2010, 75:6605-6613.
93. Martínez Montero S., Fernández S., Sanghvi Y.S., Gotor V., Ferrero M. CALB-catalyzed acylation of nucleosides and role of the sugar conformation: an improved understanding of the enzyme-substrate recognition. Eur J Org Chem 2012, 28:5483-5490.
94. Mazzaferro S., Bouchemal K., Ponchel G. Oral delivery of anticancer drugs II: the prodrug strategy. Drug Discov Today 2013, 18:93-98.
95. McClean K., Preston C., Spence D., Sutton P.W., Whittall J. Biocatalytic synthesis of valaciclovir using commercial enzymes. Tetrahedron Lett 2011, 52:215-218.
96. McGuigan C., Kinchington D., Wang M.F., Nicholls S.R., Nickson C., Galpin S., et al. Nucleoside analogues previously found to be inactive against HIV may be activated by simple chemical phosphorylation. FEBS 1993, 322:249-252.
97. McGuigan C., Bourdin C., Derudas M., Hamon N., Hinsinger K., Kandil S., et al. Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. Eur J Med Chem 2013, 70:326-340.
98. Medici R., Lewkowicz E.S., Iribarren A.M. Microbial synthesis of 2,6-diaminopurine nucleosides. J Mol Catal B: Enzym 2006, 39:40-44.
99. Medici R., Lewkowicz E.S., Iribarren A.M. Arthrobacter oxydans as a biocatalyst for purine deamination. FEMS Microbiol Lett 2008, 289:20-26.
100. Medici R., Garaycoechea J.I., Valino A.L., Pereira C.A., Lewkowicz E.S., Iribarren A.M. A comparative study on phosphotransferase activity of acid phosphatases from Raoultella planticola and Enterobacter aerogenes on nucleosides, sugars, and related compounds. Appl Microbiol Biotechnol 2014, 98:3013-3022.
101. Mehellou Y., Balzarini J., McGuigan C. Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem 2009, 11:177-1791.
102. Mehellou Y., Valente R., Mottram H., Walsby E., Mills K.I., Balzarini J., et al. Phosphoramidates of 2'-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. Bioorg Med Chem Lett 2010, 18:2439-2446.
103. Mikhailopulo I.A. Biotechnology of nucleic acids constituents - state of the art and perspectives. Curr Org Chem 2007, 11:317-335.
104. Mikhailopulo I.A., Miroshnikov A.I. Biologically important nucleosides: modern trends in biotechnology and application. Mendeleev Commun 2011, 21:57-68.
105. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34:1274-1281.
106. Munagala N., Sarver A.E., Wang C.C. Converting the guanine phosphoribosyltransferase from Giardia lamblia to a hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem 2000, 275:37072-37077.
107. Munch-Petersen B., Knecht W., Camilla Lenz, Söndergaard L., Piškur J. Functional expression of a multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster and its C-terminal deletion mutants. J Biol Chem 2000, 275:6673-6679.
108. Murakami E., Bao H., Mosley R.T., Du J., Sofia M.J., Furman P.A. Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N6- or O6-substituted purine or 2-aminopurine nucleoside monophosphates. J Med Chem 2011, 54:5902-5914.
109. Narayanasamy J., Pullagurla M.R., Sharon A., Wang J., Schinazi R.F., Chu C. Synthesis and anti-HIV activity of (-)-beta-d-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. Antiviral Res 2007, 75:198-209.
110. Nóbile M., Terreni M., Lewkowicz E., Iribarren A.M. Aeromonas hydrophila strains as biocatalysts for transglycosylation. Biocatal Biotransform 2010, 28:395-402.
111. Nóbile M., Médici R., Terreni M., Lewkowicz E.S., Iribarren A.M. Use of Citrobacter koseri whole cells for the production of arabinonucleosides: a larger scale approach. Process Biochem 2012, 47:2182-2188.
112. Palacio C.M., Sabaini M.B., Iribarren A.M., Iglesias L.E. An efficient and mild access to N-acetylated protected purine nucleosides based on a chemoselective enzymatic hydrolysis. J Biotechnol 2013, 165:99-101.
113. Pałasz A., Ciez˙ D. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: synthesis, biological activity and applications. Eur J Med Chem 2014, [in press]. 10.1016/j.ejmech.2014.10.008.
114. Parker W.B., Allan P.W., Hassan A., Secrist J.A., Sorscher E.J., Waud W.R. Antitumor activity of 2-fluoro-2-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003, 10:23-29.
115. Parker W.B., Allan P.W., Waud W.R., Hongand J.S., Sorscher E.J. Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purinenucleoside phosphorylase. Cancer Gene Ther 2011, 18:390-398.
116. Patel R.N. Synthesis of chiral pharmaceutical intermediates by biocatalysis. Coord Chem Rev 2008, 252:659-701.
117. Pei L., Xie L., Lin Q., Ling X., Guan Z., Yang Z. Studies on the adenosine deaminase-catalyzed conversion of adenosine and nucleoside prodrugs by different capillary electrophoresis modes. Anal Biochem 2011, 414:131-137.
118. Pertusati F., Serpi M., McGuigan C. Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antivir Chem Chemother 2012, 22:181-203.
119. Peyrottes S., Egron D., Lefebvre I., Gosselin G., Imbach J.L., Périgaud C. SATE pronucleotide approaches: an overview. Mini Rev Med Chem 2004, 4:395-408.
120. Pierra C., Amador A., Benzaria S., Cretton-Scott E., D'Amours M., Mao J., et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J Med Chem 2006, 49:6614-6620.
121. Pradere U., Garnier-Amblard U.C., Coats S.J., Amblard F., Schinazi R.F. Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev 2014, 114:9154-9218.
122. Prichard M.N., Keith K.A., Johnson M.P., Harden E.A., McBrayer A., Luo M., et al. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother 2007, 51:1795-1803.
123. Qian Y., Ding Q., Li Y., Zou Z., Yan B., Ou L. Phosphorylation of uridine and cytidine by uridine-cytidine kinase. J Biotechnol 2014, 188:81-87.
124. Rasmussen U.B., Mygind B., Nygaard P. Purification and some properties of uracil phosphoribosyitransferase from Escherichia coli K12. Biochim Biophys Acta 1986, 881:268-275.
125. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Järvinen T., et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008, 7:255-270.
126. Ray A.S., Hostetler K.Y. Application of kinase bypass strategies to nucleoside antivirals. Antiviral Res 2011, 92:277-291.
127. Ricci F., Tedeschi A., Morra E., Montillo M. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manage 2009, 5:187-207.
128. Robak P., Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 2013, 39:851-861.
129. Robak T., Korycka A., Lech-Maranda E., Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 2009, 14:1183-1226.
130. Sabaini M.B., Zinni M.A., Mohorcic M., Friedrich J., Iribarren A.M., Iglesias L.E. Enzymatic regioselective and complete deacetylation of two arabinonucleosides. J Mol Catal B Enzym 2010, 62:225-229.
131. Schimandle C.M., Mole L.A., Sherman I.W. Purification of hypoxanthine-guanine phosphoribosyltransferase of Plasmodium lophurae. Mol Biochem Parasitol 1987, 23:39-45.
132. Scism R.A., Bachmann B.O. Five-component cascade synthesis of nucleotide analogues in an engineered self-immobilized enzyme aggregate. Chembiochem 2010, 11:67-70.
133. Scism R.A., Stec D.F., Bachmann B.O. Synthesis of nucleotide analogous by a promiscuous phosphoribosyltransferase. Org Lett 2007, 9:4179-4182.
134. 19 NMR studies of 2-fluoroadenine-substituted RNA. J Am Chem Soc 2004, 126:11776-11777.
135. Serra I., Bavaro T., Cecchini D.A., Daly S., Albertini A.M., Terreni M., et al. A comparison between immobilized pyrimidine nucleoside phosphorylase from Bacillus subtilis and thymidine phosphorylase from Escherichia coli in the synthesis of 5-substituted pyrimidine 2-deoxyribonucleosides. J Mol Catal B Enzym 2013, 95:16-22.
136. Serra I., Conti S., Piskur J., Clausen A.R., Munch-Petersen B., Terreni M., et al. Immobilized Drosophila melanogaster deoxyribonucleoside kinase (DmdNK) as a high performing biocatalyst for the synthesis of purine arabinonucleotides. Adv Synth Catal 2014, 356:563-570.
137. Sharif H., Kiran K.J., Wang L., He E., Eriksson S. Quaternary structures of recombinant, cellular, and serum forms of Thymidine Kinase 1 from dogs and humans. Biochemistry 2012, 13:12.
138. Shimma N., Umeda I., Arasaki M., Murasaki C., Masubuchi K., Kohchi Y., et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem 2000, 8:1697-1706.
139. Singh R., Vince R. 2-Azabicyclo[2.2.1]hept-5-en-3-one: chemical profile of a versatile synthetic building block and its impact on the development of therapeutics. Chem Rev 2012, 112:4642-4686.
140. Sjöberg A.H., Wang L., Eriksson S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol Pharmacol 1998, 53:270-273.
141. Sofia M.J. Nucleotide prodrugs for HCV therapy. Antivir Chem Chemother 2011, 22:23-49.
142. Sofia M.J., Furman P.A., Symonds W.T. 2'-F-2'-C-methyl nucleosides and nucleotides for the treatment of hepatitis C virus: from discovery to the clinic. RSC Drug Discovery Ser. Royal Society of Chemistry 2010, 238-266. J.C. Barrish, P.H. Carter, P.T.W. Cheng, R. Zahlers (Eds.).
143. Sorscher E.J., Peng S., Bebok Z., Allan P.W., Bennett L.L.J., Parker W.B. Tumor cell bystander killing in colonic carcinoma utilizing the E. coli DeoD gene and generation of toxic purines. Gene Ther 1994, 1:233-238.
144. Soysa R., Wilson Z.N., Elferich J., Forquer I., Shinde U., Riscoe M.K., et al. Substrate inhibition of uracil phosphoribosyltransferase by uracil can account for the uracil growth sensitivity of Leishmania donovani pyrimidine auxotrophs. J Biol Chem 2013, 288:29954-29964.
145. Stankova I., Stanoeva K., Hinkov A., Alexiev I., Genova-Kalou P., Chayrov R., et al. Amino acid and peptide esters of abacavir: synthesis and activity against human immunodeficiency virus type 1 in cell culture. Med Chem Res 2012, 21:4053-4059.
146. Stella V.J. Prodrugs: some thoughts and current issues. J Pharm Sci 2010, 99:4755-4765.
147. Stella V.J., Nti-Addae K.W. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 2007, 59:677-694.
148. Suzuki N.N., Koizumi K., Fuyushima, Matsuda A., Inagaki F. Structural basis for specificity, catalysis and regulation of human uridine-cytidine kinase. Structure 2004, 12:751-764.
149. Sznaidman M., Painter G.R., Almond M.R., Cleary D.G., Pesyan A. WO2005074654 2005.
150. Tai C.K., Wang W., Lai Y.H., Logg C.R., Parker W.B., Li Y.F., et al. Enhanced efficiency of prodrug activation therapy by tumor-selectively replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2010, 17:614-623.
151. Tanaka N., Hasan Z., Hartog A.F., van Herk T., Wever R. Phosphorylation and dephosphorylation of polyhydroxy compounds by class A bacterial acid phosphatase. Org Biomol Chem 2003, 1:2833-2839.
152. Tardibono L.P., Miller M.J., Balzarini J. Enantioselective syntheses of carbocyclic nucleosides 5'-homocarbovir, epi-4'-homocarbovir, and their cyclopropylamine analogs using facially selective Pd-mediated allylations. Tetrahedron 2011, 67:825-829.
153. Turttle J.V., Krenitsky T.A. Purine phosphoribosyltransferase from Leishmania donovani. J Biol Chem 1980, 255:909-916.
154. Ubiali D., Serra C.D., Serra I., Morelli C.F., Terreni M., Albertini A.M., et al. Production, characterization and synthetic application of a purine nucleoside phosphorylase from Aeromonas hydrophila. Adv Synth Catal 2012, 354:96-104.
155. Ullman B., Cyr N., Choi K., Jardim A. Acidic residues in the purine binding site govern 6-oxopurine specificity of the Leishmania donovani xanthine phosphoribosyltransferase. Int J Biochem Cell Biol 2010, 42:253-262.
156. Van Herk T., Hartog A.F., van der Burg A.M., Wever R. Regioselective phosphorylation of carbohydrates and various alcohols by bacterial acid phosphatases; probing the substrate specificity of the enzyme from Shigella flexneri. Adv Synth Catal 2005, 347:1155-1162.
157. Vig B.S., Huttunen K.M., Laine K., Rautio J. Amino acids as promoieties in prodrug design and development. Adv Drug Deliv Rev 2013, 65:1370-1385.
158. Wang Z.Y., Zong M.H. Recognition of acyl donors by lipase CAL-B in the acylation of 6-azauridine. Biotechnol Prog 2009, 25:784-791.
159. Wang Z.Y., Li N., Zong M.H. A simple procedure for the synthesis of potential 6-azauridine prodrugs by Thermomyces lanoginosus lipase. J Mol Catal B: Enzym 2009, 59:212-219.
160. Wang Z.Y., Bi Y.H., Zong M.H. Highly regioselective synthesis of 3'-O-acyl-trifluridines catalyzed by Pseudomonas cepacia lipase. Appl Biochem Biotechnol 2011, 165:1161-1168.
161. Wang Z.Y., Bi Y.H., Zong M.H. Regioselectivity-reversal in acylation of 6-azauridine catalyzed by Burkholderia cepacia lipase. Biotechnol Lett 2012, 34:55-59.
162. Wang Z.Y., Bi Y.H., Zong M.H. Regioselective enzymatic procedure for preparing 3'-O-stearoyl-6-azauridine by using Burkholderia cepacia lipase. Biotechnol Bioprocess Eng 2012, 17:393-397.
163. Wang Z.Y., Bi Y.H., Li X.Q., Zong M.H. Influence of substituent groups in regioselective acylation of nucleosides by Novozym 435 lipase. Process Biochem 2013, 48:1208-1211.
164. Wang J., Zhu J., Min C., Wu S. CBD binding domain fused gamma-lactamase from Sulfolobus solfataricus is an efficient catalyst for (-) gamma-lactam production. BMC Biotechnol 2014, 14:40.
165. Weckbecker G., Cory J.G. 2,6-Diaminopurinedeoxyriboside as a prodrug of deoxyguanosine in L1210 cells. Cancer Res 1987, 47:2218-2223.
166. Wu J.Z., Larson G., Walker H., Shim J.H., Hong Z. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005, 49:2164-2171.
167. Xu F., Zhang M., Wu Q., Lin X. Novel l-amino acid ester prodrugs of azacitidine: design, enzymatic synthesis and the investigation of release behaviour. J Mol Catal B Enzym 2014, 105:49-57.
168. Yan L.Q., Li N., Zong M.H. First and facile enzymatic synthesis of β-fucosyl-containing disaccharide nucleosides through β-galactosidase-catalysed regioselective glycosylation. J Biotechnol 2012, 164:371-375.
169. Yan L.Q., Li N., Zong M.H. First enzymatic galactosylation of acyclic nucleoside drugs by β-galactosidase: synthesis of water-soluble β-d-galactosidic prodrugs. Biotechnol Bioprocess Eng 2014, 19:586-591.
170. Yang M.Y., Wu H., Lu Z.H., Li X.F., Lai F.R., Zhao L.G. Regioselective synthesis of cytarabine monopropionate by using a fungal whole-cell biocatalyst in nonaqueous medium. Bioorg Med Chem Lett 2014, 24:3377-3380.
171. Ye M., Yu C.Y., Li N., Zong M.H. Highly regioselective glucosylation of 2'-deoxynucleosides by using the crude β-glycosidase from bovine liver. J Biotechnol 2011, 155:203-208.
172. Ye M., Yan L.Q., Li N., Zong M.H. Facile and regioselective enzymatic 5'-galactosylation of pyrimidine 2'-deoxynucleosides catalyzed β-glycosidase from bovine liver. J Mol Catal B Enzym 2012, 79:35-40.
173. Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr Int 2002, 44:196-198.
174. Zawilska J.B., Wojcieszak J., Olejniczak A.B. Prodrugs: a challenge for the drug development. Pharmacol Rep 2013, 65:1-14.
175. Zeiner G.M., Cleary M.D., Fouts A.E., Meiring C.D., Mocarski E.S., Boothroyd J.C. RNA analysis by biosynthetic tagging using 4-thiouracil and uracil phosphoribosyltransferase. Methods Mol Biol 2008, 419:135-146.
176. Zeng Q.M., Li N., Zong M.H. Highly regioselective galactosylation of floxuridine catalysed by β-galactosidase from bovine liver. Biotechnol Lett 2010, 32:1251-1254.
177. Zhang Y., Gao Y., Wen X., Ma H. Current prodrug strategies for improving oral absorption of nucleoside analogues. Asian J Pharm Sci 2014, 9:65-74.
178. Zhernosek E.V., Kvach S.V., Eroshevskaya L., Kalinichenko E.N., Zinchenko A.I. Synthesis of conjugates of 2',3'-dideoxynucleoside-5'-monophosphate with α-amino acids. Chem Nat Compd 2006, 42:208-211.
179. Zhou L., Coats S.J., Zhang H., Shi H., Bobeck D.R., Schinazi R.F. Scaleable processes for the synthesis of (-)-beta-d-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (-)-beta-d-2-aminopurine dioxolane (APD). Tetrahedron 2012, 68:5738-5743.
180. Zhu S., Song D., Gong C., Tang P., Li X., Wang J., et al. Biosynthesis of nucleoside analogues via thermostable nucleoside phosphorylase. Appl Microbiol Biotechnol 2013, 97:6769-6778.
181. Zhu S., Ren L., Yu S., Gong C., Song D., Zheng G. Enzymatic preparation of optically pure(+)-2-azabicyclo[2.2.1]hept-5-en-3-one by (-)-gamma-lactamase from Bradyrhizobium japonicum USDA 6S. Bioorg Med Chem Lett 2014, 24:4899-4902.
182. Zinchenko A.I., Barai V.N., Zalashko L., Poopeiko N.E., Pricota T.I., Sivets G.G., et al. Enzymatic synthesis of nucleoside 5'-mono and triphosphates. FEBS Lett 1990, 260:254-256.
183. Zou Z., Ding Q., Ou L., Yan B. Efficient production of deoxynucleoside-5'-monophosphates using deoxynucleoside kinase coupled with a GTP-regeneration system. Appl Microbiol Biotechnol 2013, 97:9389-9395.
184. Zuffi G., Ghisotti D., Oliva I., Capra E., Frascotti G., Tonon G., et al. Immobilized biocatalysts for the production of nucleosides and nucleoside analogues by enzymatic transglycosylation reactions. Biocatal Biotransform 2004, 22:25-33.